ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
Bouncing
|
59 |
15K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
59
|
15K
|
1
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Sale of Jendale Property
|
|
Bouncing
|
10 |
1.3K |
2 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
10
|
1.3K
|
2
|
|
ASX - By Stock
|
DNA |
Re:
Ann: Quarterly Activities and Cashflow Reports
|
|
Bouncing
|
11 |
2.0K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
11
|
2.0K
|
0
|
|
ASX - By Stock
|
DNA |
Re:
Ann: Quarterly Activities and Cashflow Reports
|
|
Bouncing
|
11 |
2.0K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
11
|
2.0K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bouncing
|
10K |
4.4M |
12 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
10K
|
4.4M
|
12
|
|
ASX - By Stock
|
AZI |
Re:
Ann: Lazio Lithium Project Maiden Mineral Resource Estimate
|
|
Bouncing
|
2 |
854 |
1 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
2
|
854
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
Bouncing
|
37 |
8.8K |
1 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
8.8K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Bile Tract Cancer Study Opens after MAST High Dose Clearance
|
|
Bouncing
|
163 |
62K |
2 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
163
|
62K
|
2
|
|
ASX - By Stock
|
PIL |
Re:
Daily Price Movement / General Discussion
|
|
Bouncing
|
2.8K |
837K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
2.8K
|
837K
|
0
|
|
ASX - By Stock
|
PIL |
Re:
Daily Price Movement / General Discussion
|
|
Bouncing
|
2.8K |
837K |
3 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
2.8K
|
837K
|
3
|
|
ASX - By Stock
|
PIL |
Re:
Ann: More technical integration contracts with Strategic Partners
|
|
Bouncing
|
21 |
5.5K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
21
|
5.5K
|
0
|
|
ASX - By Stock
|
CXO |
Re:
Banter and general comments
|
|
Bouncing
|
38K |
17M |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
38K
|
17M
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bouncing
|
10K |
4.4M |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
10K
|
4.4M
|
0
|
|
ASX - By Stock
|
TAL |
Re:
Ann: Talius Group enters MSA with Hato Hone St John
|
|
Bouncing
|
4 |
1.4K |
2 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
4
|
1.4K
|
2
|
|
ASX - By Stock
|
TAL |
Re:
Ann: Talius Group enters MSA with Hato Hone St John
|
|
Bouncing
|
4 |
1.4K |
3 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Bouncing
|
1.3K |
328K |
10 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
1.3K
|
328K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Bouncing
|
1.3K |
328K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
1.3K
|
328K
|
3
|
|
ASX - By Stock
|
CXO |
Re:
Banter and general comments
|
|
Bouncing
|
38K |
17M |
7 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
38K
|
17M
|
7
|
|
ASX - By Stock
|
WWG |
Re:
Ann: 1H24 Results Presentation
|
|
Bouncing
|
6 |
2.4K |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
6
|
2.4K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
Bouncing
|
316 |
160K |
24 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
316
|
160K
|
24
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVE
|
|
Bouncing
|
22 |
8.3K |
3 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
22
|
8.3K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVE
|
|
Bouncing
|
22 |
8.3K |
7 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
22
|
8.3K
|
7
|
|
ASX - By Stock
|
TAL |
Re:
Ann: Talius Group Start of 2024 Update
|
|
Bouncing
|
2 |
1.1K |
0 |
09/01/24 |
09/01/24 |
ASX - By Stock
|
2
|
1.1K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at Biotech Showcase at JPM week
|
|
Bouncing
|
19 |
7.1K |
1 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
19
|
7.1K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bouncing
|
10K |
4.4M |
9 |
22/12/23 |
22/12/23 |
ASX - By Stock
|
10K
|
4.4M
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Ann: ADVENT-AML clinical trial GMP manufacturing complete
|
|
Bouncing
|
8 |
4.0K |
7 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
8
|
4.0K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
Bouncing
|
208 |
85K |
28 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
208
|
85K
|
28
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Phase 1B ADVENT-AML trial to be presented at ASH meeting
|
|
Bouncing
|
7 |
2.9K |
3 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
7
|
2.9K
|
3
|
|
ASX - By Stock
|
TAL |
Re:
Ann: Talius Group Completes $2.5 Million Placement
|
|
Bouncing
|
4 |
1.8K |
1 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
4
|
1.8K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Entitlement Offer
|
|
Bouncing
|
44 |
12K |
4 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
44
|
12K
|
4
|
|
ASX - By Stock
|
PCK |
Re:
PCK Chart
|
|
Bouncing
|
89 |
35K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
89
|
35K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bouncing
|
10K |
4.4M |
5 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
10K
|
4.4M
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Bouncing
|
99 |
31K |
3 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
99
|
31K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Bouncing
|
99 |
31K |
0 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
99
|
31K
|
0
|
|
ASX - By Stock
|
PIL |
Re:
Daily Price Movement / General Discussion
|
|
Bouncing
|
2.8K |
837K |
9 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
2.8K
|
837K
|
9
|
|
ASX - By Stock
|
SHV |
Re:
Ann: FY2023 Results Presentation
|
|
Bouncing
|
80 |
30K |
0 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
80
|
30K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Positive in vitro data for CHM 1301 CAR NK cells
|
|
Bouncing
|
79 |
19K |
2 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
79
|
19K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Positive in vitro data for CHM 1301 CAR NK cells
|
|
Bouncing
|
79 |
19K |
0 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
79
|
19K
|
0
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Bouncing
|
1.6K |
831K |
2 |
15/11/23 |
15/11/23 |
Charts
|
1.6K
|
831K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
Bouncing
|
51 |
28K |
0 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
51
|
28K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
Bouncing
|
51 |
28K |
4 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
51
|
28K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
Bouncing
|
51 |
28K |
1 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
51
|
28K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
|
|
Bouncing
|
51 |
28K |
0 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
51
|
28K
|
0
|
|
ASX - By Stock
|
EOS |
Re:
Ann: EOS update re dispute with lender WHSP
|
|
Bouncing
|
4 |
2.4K |
0 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
4
|
2.4K
|
0
|
|
ASX - By Stock
|
ICI |
Re:
Ann: Becoming a substantial holder
|
|
Bouncing
|
21 |
5.0K |
0 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
21
|
5.0K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
Bouncing
|
70 |
20K |
2 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
70
|
20K
|
2
|
|
ASX - By Stock
|
DNA |
Re:
Ann: Quarterly Activities and Cashflow Reports
|
|
Bouncing
|
27 |
9.0K |
0 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
27
|
9.0K
|
0
|
|
ASX - By Stock
|
NTU |
Re:
Ann: Trading Halt
|
|
Bouncing
|
6 |
2.0K |
0 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
6
|
2.0K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Bouncing
|
99 |
31K |
8 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
99
|
31K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Bouncing
|
99 |
31K |
3 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
99
|
31K
|
3
|
|